Aralez Pharmaceuticals (ARLZ) Receives Daily Media Impact Score of 0.15
News stories about Aralez Pharmaceuticals (NASDAQ:ARLZ) have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aralez Pharmaceuticals earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.6140917965627 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Aralez Pharmaceuticals (NASDAQ ARLZ) traded up 5.53% on Friday, reaching $2.29. 1,595,958 shares of the company’s stock were exchanged. The firm’s market cap is $153.08 million. Aralez Pharmaceuticals has a 12 month low of $0.95 and a 12 month high of $5.90. The firm’s 50-day moving average is $1.19 and its 200-day moving average is $1.54.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last announced its quarterly earnings results on Wednesday, August 9th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.01). The firm had revenue of $27.62 million during the quarter, compared to analyst estimates of $21.37 million. Aralez Pharmaceuticals had a negative net margin of 122.35% and a negative return on equity of 90.17%. The business’s revenue was up 119.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.27) EPS. On average, equities analysts forecast that Aralez Pharmaceuticals will post ($1.62) earnings per share for the current year.
Separately, Chardan Capital cut their target price on shares of Aralez Pharmaceuticals from $5.50 to $4.00 and set a “buy” rating for the company in a research report on Thursday, August 10th.
TRADEMARK VIOLATION NOTICE: “Aralez Pharmaceuticals (ARLZ) Receives Daily Media Impact Score of 0.15” was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/aralez-pharmaceuticals-arlz-receives-daily-media-impact-score-of-0-15/1601221.html.
About Aralez Pharmaceuticals
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.